Chunxi (Chauncey) Zeng
About Chunxi (Chauncey) Zeng
Chunxi (Chauncey) Zeng is a Scientist II at Tessera Therapeutics in Cambridge, Massachusetts, where he has worked since 2021. He holds a Ph.D. in Biochemistry, Molecular & Cellular Biology from Ohio University and has experience in RNA and drug discovery.
Work at Tessera Therapeutics
Chunxi Zeng has been employed at Tessera Therapeutics as a Scientist II since 2021. In this role, he contributes to the development of the company's Gene Writing™ technology by designing novel mRNAs. His work focuses on utilizing his expertise in RNA and drug discovery to advance gene editing applications. Tessera Therapeutics is based in Cambridge, Massachusetts, where Zeng applies his knowledge to innovative projects in the biotechnology sector.
Education and Expertise
Chunxi Zeng earned a Doctor of Philosophy (Ph.D.) in Biochemistry, Molecular & Cellular Biology, and RNA Drug Discovery from Ohio University, where he studied from 2009 to 2015. Prior to this, he obtained a Bachelor of Science (BS) in Biotechnology from Sichuan University, completing his degree from 2000 to 2004. His educational background provides a strong foundation for his current research and development efforts in RNA and drug discovery.
Background
Before joining Tessera Therapeutics, Chunxi Zeng held several academic and research positions. He worked as an Adjunct Lecturer at Ohio University for three months in 2016. He also served as a Research Scientist at The Ohio State University Wexner Medical Center from 2020 to 2021. Additionally, he worked as a Postdoc/Research Associate at Ohio State University, where he focused on advanced research projects related to his field.
Research and Contributions
Chunxi Zeng has made significant contributions to the field of biotechnology through his work on mRNA design for gene editing applications. His experience in RNA and drug discovery is integral to the projects he undertakes at Tessera Therapeutics. His role involves applying scientific principles to develop innovative solutions in gene therapy, which aligns with the company's mission to transform medicine through its Gene Writing™ technology.